Key result
Fumarate therapy is linked to ~16% fewer infections versus anti-CD20s by year two.
Why the study?
Patients with multiple sclerosis treated with anti-CD20 monoclonal antibodies face an increased infection risk, but long-term comparative data versus oral fumarates are limited.
Do fumarates reduce infection risk compared to anti-CD20 monoclonal antibodies in people with multiple sclerosis?
Cohort (n=1,956)
Do fumarates reduce infection risk compared to anti-CD20 monoclonal antibodies in people with multiple sclerosis?
Fumarate therapy is associated with a lower and more stable long-term infection risk compared to anti-CD20 monoclonal antibodies in patients with multiple sclerosis.
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“While early intervention with a high-efficacy disease-modifying therapy may improve long-term outcomes, transitioning to a moderate-efficacy oral DMT such as dimethyl fumarate may mitigate safety and tolerability concerns after stabilization of disease activity.”
“In a comparative study of nearly 2000 patients with multiple sclerosis (MS), findings showed that those on long-term fumarates (FUM) had significantly lower infection-related healthcare resource utilization (HCRU) over a 2-year follow-up than those on anti-CD20-targeting medications. Overall, these data underscored the importance of long-term risk-benefit considerations when selecting disease-modifying therapies in MS management. The study revealed a significantly lower number of annualized infection-related healthcare encounter rate per patient per year (PPPY) with FUM relative to anti-CD20s (1.75 vs 2.22; P <.001).”
“Given the risk of severe infections, particularly in older people with MS who have higher rates of infection-related hospitalization and mortality, this study provides important considerations for treatment in these populations.”
May support fumarate switch to reduce infection-related utilization in stable MS; hypothesis-generating and requires prospective confirmation.
Background: People with multiple sclerosis (pwMS) treated with anti-CD20 monoclonal antibodies have an elevated infection risk, yet long-term comparative data with oral fumarates are limited. Objective: To compare infection incidence, healthcare resource utilization, and relapse outcomes among pwMS receiving fumarate or anti-CD20 therapy for ⩾2 years. Methods: This retrospective propensity-matched (1:2) analysis used US Komodo Health claims (1 January 2016–31 May 2022) for pwMS aged 18–64 years with ⩾2 years of continuous follow-up. Outcomes were assessed using Poisson generalized linear models. Results: A total of 1956 pwMS were matched (fumarates: n = 652; anti-CD20s: n = 1304), with mean follow-up ~3 years. By year 2, the fumarates group had a lower infection rate than anti-CD20s (rate ratio: 0.84; 95% CI: 0.73–0.97; p = 0.016), but the most substantial difference was observed in years 4+, where fumarate-treated patients had a 30% reduction versus anti-CD20s (rate ratio: 0.70; 95% CI: 0.52–0.95; p = 0.021). Conclusions: Fumarate therapy was associated with a lower infection risk versus anti-CD20s. The infection rate in the fumarates group remained relatively stable over time, but it progressively increased in the anti-CD20 group, with the most prominent differences observed at year 4 and beyond.
No takes yet. Share an insight, caveat, or question.
Smoot et al. (2026) conducted a cohort in multiple sclerosis (n=1,956). Fumarates vs. Anti-CD20 monoclonal antibodies was evaluated on Infection incidence by year 2 (rate ratio 0.84, 95% CI 0.73-0.97, p=0.016). Fumarate therapy was associated with a lower infection rate versus anti-CD20s by year 2, with differences progressively increasing at year 4 and beyond.
Synapse has enriched 10 related papers. Consider them for comparative context: